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Summary A multimeric peptide, Ac-Y16, consisting of 16 YIGSR sequences from laminin was evaluated for
its effect on experimental metastasis, angiogenesis and tumour growth of HT1080 human fibrosarcoma cells.
Co-injection of 0.5 mg per mouse of Ac-Y16 i.v. with HT1080 cells inhibited lung colonisation by 100%,
whereas 0.5 mg per mouse ofmonomeric Ac-YIGSR-NH2(Ac-Y1) inhibited by 94%. Ac-Y16 did not show any
direct cytotoxicity on tumour cells in vivo. The effect of the peptides on angiogenesis and tumour growth
respectively were evaluated by counting areas ofneovessels and weighing tumours after the s.c. implantation of
HT1080 cells with basement membrane extracts and the peptide into nude mice. Co-injection of 0.5 mg per
mouse ofAc-Y16 s.c. with HT1080 cells inhibited angiogenesis and tumour growth by 92% (P<0.05) and 76%
(P<0.05) respectively, whereas 0.5 mg per mouse of monomeric Ac-YIGSR-NH2(Ac-YI) inhibited
angiogenesis and tumour growth by 40% (P<0.05) and 9% (P>0.05) respectively. It can be inferred from
these data that anti-tumour effects of Ac-Y16 are likely to result from anti-angiogenesis. Intraperitoneal
administration ofAc-Y16 was also effective in inhibiting angiogenesis, tumour growth and lung colonisation of
HT1080 cells. It was concluded that the multimeric YIGSR-containing peptide, Ac-Y16, inhibits angiogenesis,
tumour growth and experimental metastasis more than the monomeric form and that it is active when
administered i.p., i.v. and s.c.
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Laminin, a major component of basement membranes, is a
large glycoprotein (Mr =900 000) that promotes the adhesion,
growth, migration, neurite outgrowth, differentiation and
metastasis of a variety of cells (Martin and Timpl, 1987).
Laminin-1, the best characterised laminin, is composed of
three chains, designated a-I (formerly A, Mr=400 000), 3-1
(formerly Bi, M =210 000) and y-l (formerly B2, M =200
000), which are assembled into a triple-stranded coiled-coil
structure at the long arm (Burgeson et al., 1994). The chains
of laminin- 1 have been cloned, sequenced (Sasaki and
Yamada, 1987; Sasaki et al., 1987, 1988) and attempts have
been made to use such sequence data to define the active sites
on laminin-I using synthetic peptides (Graf et al., 1987;
Iwamoto et al., 1988; Charonis et al., 1988; Kleinman et al.,
1989; Tashiro et al., 1989, 1991; Grant et al., 1989). The
YIGSR sequence located on the ,B-1 chain (positions 929-
933) has been shown to promote cell adhesion, and migration
and to inhibit angiogenesis (Graf et al., 1987; Iwamoto et al.,
1988; Grant et al., 1989; Sakamoto et al., 1991). The peptide
has also been shown to inhibit experimental metastasis and
s.c. tumour growth (Iwamoto et al., 1987, 1992b; Kawasaki et
al., 1991; Murata et al., 1989; Nakai et al., 1992; Sakamoto et
al., 1991). These findings suggest that the YIGSR peptide is a
potential candidate for development of anti-cancer and anti-
metastatic agents.
Several modifications of YIGSR peptides have been
reported to enhance the activity. Changes in the structure
of the YIGSR sequence may be effective for the enhancement
of its anti-tumour activity since the polymerised YIGSR
peptide more effectively inhibits experimental metastasis than
the monomeric peptide (Murata et al., 1989). In addition,
coupling to polyethylene glycol has also led to an increase in
activity (Kawasaki et al., 1991). Based on the conformational
studies by NMR and computer modelling (Ostheimer et al.,
1992) and the increased anti-tumour activity observed with
the cyclic YIGSR (Kleinman et al., 1989), the turn structure
of the YIGSR peptides has been suggested to be important
for the activity. Based on these results, the multimeric
YIGSR peptide (CH3CO-Tyr-lle-Gly-Ser-Arg-Gly)16-Lys8-
Lys4-Lys2-Lys-Gly [(Ac-YIGSRG)16K8K4K2KG] (designated
Ac-Y16) has been designed and its potentiated anti-tumour
effect on mouse melanoma cells has been reported (Nomizu
et al., 1993). Moreover, the multimeric peptide has recently
been reported to induce apoptosis in HT1080 human
fibrosarcoma cells in vitro (Kim et al., 1994). We report
that a multimeric YIGSR peptide designated Ac-Y16 reduces
the growth and experimental metastasis of HT1080 human
fibrosarcoma cells. Our angiogenesis assay in vivo indicates
that Ac-Y16 inhibits angiogenesis. It is likely that the anti-
tumour effects of Ac-Y16 is a result of anti-angiogenic
activity of Ac-Y16.
Materials and methods
Materials
Peptides were synthesised as described previously (Nomizu et
al., 1993). Briefly, the linear peptides, Ac-YIGSR-NH2(Ac-
Y1) and KLQSLDLSAAAQMTCGTPPGA (P4), were
synthesised by the solid-phase method using an Applied
Biosystems 431A automated peptide synthesiser on tert-
butyloxycarbonyl strategy. Deprotection and cleavage from
the resin were achieved by treatment with anhydrous
hydrogen fluoride and the crude peptides were purified by
reversed-phase high-performance liquid chromatography
(HPLC). A multimeric form of YIGSR, Ac-Y16, was
synthesised manually by the 9-fluorenylmethyloxycarbonyl
(Fmoc) strategy on Wang-type resin (Fmoc-Gly-resin 0.1
mmol g-') using diisopropylcarbodiimide-N-hydroxybenzo-
triazole coupling and N-Fmoc deprotection with 20% (v/v)
piperidine/dimethylformamide. Deprotection and cleavage
from the resin were achieved by treatment with 1 M
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trimethylsilylbromide-thioanisole in trifluoroacetic acid (0 °C,
2 h) (Yajima et al., 1988). The crude peptides were purified
by reversed-phase HPLC. The identity of the peptides was
confirmed by amino acid analysis.
Mouse laminin-1 was extracted and purified from the
Engelbreth-Holm-Swarm (EHS) tumour, as described
previously (Timpl et al., 1979).
Matrigel, an extract of EHS tumour rich in basement
membrane proteins (Kleinman et al., 1986), was purchased
from Becton Dickinson Labware (Bedford, MA, USA). The
protein concentration of Matrigel used throughout the
present study was 10 mg ml-'.
Animals and tumour
Female 6-week-old Balb/c nu/nu mice were obtained from
SLC (Shizuoka, Japan). Throughout the experiments, the
mice were maintained in a laminar flow cabinet under specific
pathogen-free conditions.
Female 5-week-old DDD mice were used to assess the
effect of Ac-Y16 on the growth of Ehrlich solid and ascitic
tumours. Ehrlich ascitic tumour cells (Kimura et al., 1980),
obtained from Dr S Taniguchi, Kyushu University, were
maintained in the DDD mice and passaged routinely in
ascites form. The mice were provided with food and water ad
libitum.
Cells and culture
HT1080 cells from a human fibrosarcoma (Rasheed et al.,
1974) were maintained in Dulbecco's modified Eagle medium
(DMEM) supplemented with 10% fetal calf serum (FCS),
100 units ml-' penicillin and 100 ig ml-' streptomycin
(Gibco).
Cell adhesion assay
Cell adhesion was assayed as described previously (Nomizu et
al., 1992). Briefly, various concentrations of either laminin-1
or peptides, which were dissolved in water were added to 96-
well dishes (Immulon 2, Dynatech, Alexandria, VA, USA)
and dried at room temperature overnight. The laminin- or
peptide-coated wells were gently washed once with phos-
phate-buffered saline without Ca2+ and Mg2+ (PBS-), and
any uncoated surfaces were subsequently blocked with 0.1 ml
of DMEM per well containing 1% heat-inactivated bovine
serum albumin (BSA) for 1 h at 37°C. The solution was then
removed gently, and HT1080 cells (5 x 104) were added to
each well in a total volume of 0.1 ml of serum-free DMEM
containing 0.2% BSA and incubated for 30 min at 37°C in
5% carbon dioxide/95% air. Wells were then washed with
PBS- to remove unattached cells. Attached cells were stained
with 0.1% crystal violet followed by measurement of optical
density (OD) at 560 nm.
Inhibition assay
Inhibition of attachment to laminin-1 was assayed as
previously described (Nomizu et al., 1992). Ninety-six-well
dishes (Immulon 2) were coated with laminin-l (1 pg per
well) and blocked with DMEM and inactivated BSA as
described above. Various amounts of peptides were mixed
with HT1080 cells (5 x 104) and added to each well in a total
volume of 0.1 ml. After incubation for 30 min, wells were
washed with PBS- to remove unattached cells. Attached cells
were counted as described above.
Lung tumour colonisation assay
The inhibitory effect of the peptides on lung colonisation was
assessed as described previously (Iwamoto et al., 1987).
Versene-detached HT1080 cells (1 x 106) in 0.4 ml of
minimum essential medium containing 0.5 mg of the
synthetic peptide were injected into the tail veins of mice.
Five mice were used for each group. Twenty-one days later,
the mice were sacrificed. Lungs were removed, and the
colonies that were visible over the whole lung surface were
counted with the naked eye.
In another experiment, we examined the effect of i.p.
administration of Ac-Y16 on lung colonisation. Versene-
detached HT1080 cells (1 x 106) in 0.4 ml of minimum
essential medium were injected into the tail veins of nude
mice. Five mice per group were given Ac-Y16 i.p. once a day
at a dose of 0.5 mg per mouse from day 3 to day 12 after the
inoculation of HT1080 cells. Twenty-one days later the mice
were sacrificed and the number of colonies over the whole
lung surface was counted.
In vivo tumour angiogenesis assay
Matrigel is a liquid at 4°C, but forms a solid gel immediately
after implantation into the mice (Fridman et al., 1990;
Iwamoto et al., 1991, 1992a). It has been shown by Passanati
et al. (1992) that angiogenesis is observed in vivo when
Matrigel is co-injected into mice with angiogenesis factors,
such as heparin and fibroblast growth factor. We used
Matrigel here in order to determine the effect of the peptides
on tumour angiogenesis as follows. Liquid Matrigel
maintained at 4°C was used as a vehicle to inject tumour
cells s.c. into nude mice. Nude mice (ten mice per group)
were each injected s.c. with 0.3 ml of Matrigel mixed with
1 x 105 HT1080 cells and peptides (0.5mg) near the
abdominal midline using a 26-gauge needle. The injected
Matrigel rapidly formed a single, solid gel that persisted for
over 14 days.
Five mice per group were sacrificed on day 7 after the
inoculation. The gel plugs were then removed together with
the overlying skin and the underlying peritoneum, fixed in
10% buffered formalin for at least 24 h, cleared in Histoclear,
embedded in paraffin, sectioned at 5mm thickness, depar-
affinised, stained with Masson-Trichrome and processed for
histological examination and image analysis. A computerised
image analyser, Cosmozone program (NEC PC-9801, Tokyo,
Japan), was used in order to quantitate the total area of
neovessels. Histological slides stained with Masson-Tri-
chrome stain were examined, adjusting the colour contrast
to enhance the specifically stained vessels. The vascularised
areas to be measured were chosen uniformly based on their
proximity to the skeletal muscle-collagen interface from
which the neovessels originated. Another five mice per group
were sacrificed on day 14 after the inoculation. The gel plugs
were removed and the anti-tumour effect of peptides was
evaluated by weighing the tumour nodules grown in the gels.
The presence of the tumour grown in the gel was
histologically confirmed.
In another experiment, nude mice (ten mice per group)
were each injected s.c. with 1 x 105 HT1080 cells mixed with
0.3 ml of Matrigel. Five mice per group were given peptides
i.p. once a day at a dose of 0.5 mg per mouse for 5 days. The
mice were then sacrificed on day 7 after tumour inoculation
and angiogenesis was quantitated as described above. The
remaining five mice per group were given peptides i.p. once a
day at a dose of 0.5 mg per mouse for 10 days, sacrificed on
day 14 after tumour inoculation and the tumours grown in
the Matrigel were weighed as described above.
Treatment of mice bearing Ehrlich solid or ascitic tumours
In order to rule out the direct cytotoxicity of Ac-Y16, the
effect of Ac-Y16 on the growth of the ascitic tumours was
compared with that on the growth of solid tumours. Ehrlich
ascites tumour cells were suspended in PBS- at a rate of
5 x 107 cells ml-'. A 0.1 ml of the suspension mixed with 0.5
mg Ac-Y16 was inoculated s.c. near the abdominal midline
or inoculated i.p. into a female DDD mouse. The mice were
killed on day 9 or on day 14 after the inoculation. In mice
bearing solid tumours, the tumours were removed and
weighed immediately after death. In mice bearing ascites
tumours, the ascites were collected and the number of ascites
tumour cells was counted.Results
Adhesion of HT1080 cells to peptide-coated dishes
Various concentrations of the peptides were tested for cell
attachment activity using human HT 1080 fibrosarcoma cells.
HT1080 cells adhered to Ac-Y1 coated on the plate in a
dose-dependent manner. The adhesion of the cells to Ac-Y16
was greater than that to Ac-Yl (Figure 1). A synthetic
peptide, P4 (KLQSLDLSAAAQMTCGTPPGA) from an-
other domain of the laminin f-I chain did not show any
activity.
Effect ofthe peptides on blocking HT1080 cell attachment to a
laminin-J substrate
In competition assays, Ac-Y1 and Ac-Y16 were tested for
their inhibitory activity on HT 1080 cell attachment to a
laminin-I substrate (Figure 2). In this assay, Ac-Y16 showed
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greater inhibitory activity than Ac-Y1. A synthetic peptide,
P4 (KLQSLDLSAAAQMTCGTPPGA) from another do-
main of the laminin #-I chain did not show any activity.
Effect of the peptides on blocking lung colonisation ofHT1080
cells
We next tested the effect of the laminin peptides on lung
colonisation after i.v. injection (Table I, Experiment 1). Co-
injection of 0.5 mg per mouse of Ac-YI reduced the number
of lung colonies by 94%. Two out of five mice did not have
any colonies in their lungs whereas all the mice receiving no
peptides had lung colonies. The inhibitory effect of Ac-Y16
on experimental metastasis was greater than that of Ac-Yl
and no mice had colonies in their lungs.
In another experiment, we assessed the effect of Ac-Y16
i.p. on lung colonisation (Table 1, Experiment 2). Ac-Y16 i.p.
for 10 days reduced the number of lung colonies after i.v.
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Figure 1 Attachment of HT1080 cells to peptide-coated dishes.
Various concentrations of synthetic peptides dissolved in water
were added to 96-well dishes and dried. The wells were gently
washed once with PBS-, and any uncoated surfaces were blocked
with 0.1 ml of DMEM per well containing 1% BSA for h at
37°C. The solution was then removed gently, and HT1080 cells
(5 x 104) were added to each well in a total volume of 0.1 ml of
serum-free DMEM containing 0.2% BSA and incubated for 30
min at 37°C in 5% carbon dioxide, 95% air. Wells were then
washed with PBS-. Attached cells were stained by 0.1% crystal
violet followed by measurement of OD at 560 nm. Cell
attachment activity with 0.2 Mg of laminin-l per well is taken as
100%. The data are given as means + s.e. (n=8). *P<0.05,
Mann-Whitney test.
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Figure 2 Effect of the peptides on blocking HT1080 cell
attachment to a laminin-l substrate. Ninety-six-well dishes were
coated with laminin-I (1 ,ug per well) and blocked with DMEM
and inactivated BSA. Various amounts of peptides were mixed
with HT1080 cells (5 x 104) and added to each well in the total
volume of 0.1 ml. After incubation for 30 min, wells were washed
with PBS- to remove unattached cells. Attached cells were
stained by 0.1% crystal violet followed by measurement of OD at
560 nm. The data are given as means + s.e. (n =8). *P<0.05,
Mann-Whitney test.
Table I Effect of laminin-l peptides on blocking lung colonisation of HT1080 cells
Number ofmice bearing lung coloniesl Number oflung colonies
Treatment group number ofmice tested (mean±s.e., n=5) (%)
Experiment Ja: co-injection of the peptides with HT1080 cells
Untreated control 5/5 23.6±2.1 (100%)
Ac-YI 3/5 1.2 ±0.7*(6%)
Ac-Y16 0/5 0*(0%)
Experiment 2b: ip. administration ofAc-Y16
Untreated control 5/5 20.6±2.1 (100%)
Ac-Y16 5/5 10.2+ 1.3*(50%)
a Versene-detached HT1080 cells(1 x 106) in 0.4 ml ofminimum essential medium containing 0.5 mg ofthe synthetic peptide were injected into
the tail vein ofthe mice. Twenty-one days later, themice were sacrificed. Lungswere removed and thecolonies thatwere visible overthe whole lung
surface were counted. *P<0.05, Mann - Whitney test. b Versene-detached HT1080 cells (1 x 106) in 0.4 ml of minimum essential medium were
injected into the tail vein ofthe nude mice. The mice were givenAc-Y16 i.p. once a dayat a dose of0.5 mgpermouse from day 3 to day 12 after the
inoculation. Twenty-one days later, the mice were sacrificed. Lungs were removed, and the colonies that were visible over the whole lung surface
were counted. *P<0.05, Mann - Whitney test.
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inoculation of HT1080 cells by 50%. In this experiment the
mice were given Ac-Y16 i.p. once a day from days 3-12 after
i.v. inoculation of tumour cells. Therefore, Ac-Y16 was
effective in blocking lung colonisation even after tumour cell
attachment was supposed to have occurred.
Effect oflaminin-J peptides on tumour angiogenesis andgrowth
We next tested the effect of the peptides on tumour
angiogenesis and tumour growth in a subcutaneous model
(Figure 3). Histological examination ofmice sacrificed on day
3 after the co-injection of Ac-Y16 i.p. (0.5 mg per mouse)
with 1 x 105 HT1080 cells revealed that the tumour cells
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within the Matrigel in the mouse given Ac-Y16 were viable,
as observed in the mouse inoculated with tumour cells alone
(data not shown). The histological examination of Matrigel
removed on day 7 after inoculation revealed that the
formation of neovessels within Matrigel was blocked by the
co-injection of 0.5 mg per mouse of Ac-Y16 and tumour cells
(Figure 3c and d). Co-injection of 0.5 mg per mouse of Ac-
YI with the tumour cells reduced the total areas of neovessels
to 60% ofuntreated controls. The inhibitory effect ofAc-Y16
on tumour angiogenesis was greater than that of Ac-Yl as
the total area of neovessels was only 8% of untreated
controls (Figure 3a). When angiogenesis was assayed after
daily i.p. injection of peptide in the same model, 0.5 mg of
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Figure 3 Effect of laminin-l peptides on angiogenesis. (a, c, d) Effect of co-injection of the peptides with HT1080 cells on
angiogenesis. Nude mice (five per group) were each injected s.c. with 0.3 ml of Matrigel mixed with 1 x 105 HT1080 cells and
peptides (0.5 mg) near the abdominal midline. The mice were sacrificed on day 7 after inoculation. The gels were then removed by
retaining the overlying skin and the underlying peritoneum, fixed in 10% buffered formalin, cleared in Histoclear, embedded in
paraffin, sectioned at 5 mm thickness, deparaffinised, stained with Masson-Trichrome and processed for histological examination
and image analysis. A computerised image analyser was used to quantitate the total area of neovessels. Mean vessel area of
untreated control mice was 5772 pm3. The data are given as means + s.e. (n =5) (a). *P <0.05, Mann-Whitney test. Histology of
Matrigel removed on day 7 after inoculation (c, d) Masson-Trichrome stain, 250 x. (c) Matrigel containing tumour cells alone
(control). The presence of neovessels (arrows) within Matrigel (MG) can be observed near skeletal muscle (SM) and collagen
interface. (d) Matrigel containing tumour cells and Ac-Y16. Few neovessels are observed (bar=100 gm). (b) Effect of i.p.
administration of the peptides on angiogenesis of HT1080 cells. Nude mice (five mice per group) were each injected s.c. with 1 x 105
HT1080 cells mixed with 0.3 ml of Matrigel. Five mice per group were given peptides i.p. daily at a dose of 0.5 mg per mouse for 5
days. The mice were then sacrificed on day 7 after tumour inoculation and angiogenesis was quantitated as described. Mean vessel
area of untreated control mice was 6226 pm3. The data are given as means + s.e. (n = 5). *P< 0.05, Mann-Whitney test.
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Ac-Y16 resulted in a 86% reduction in angiogenesis (Figure
3b).
Weights of tumours determined on day 14 after tumour
cell inoculation in the group given Ac-Y1 and Ac-Y16 were
91% and 24% respectively, relative to those in untreated
mice (Table II, Experiment 1). Likewise a 39% reduction in
tumour growth was observed when Ac-Y16 was administered
daily at a dose of0.5 mg per mouse (Table II, Experiment 2).
These results suggest that the inhibitory effect of peptides on
tumour angiogenesis leads to the inhibition of the tumour
growth.
Effect ofAc-Y16 on growth ofEhrlich solid and ascitic tumour
Weights of the solid tumours determined on day 9 and on
day 14 after the co-injection of Ac-Y16 (0.5 mg per mouse)
with the tumour cells were only 9% and 6% of untreated
controls respectively (Table III). In contrast, when the
tumours were grown i.p., as ascites, no significant difference
could be detected between treated and control groups.
Discussion
The multimeric peptide Ac-Y16 was prepared by the
multimeric antigen peptide (MAP) method developed by
Tam (1988), Tam and Lu (1989), in which the branched core
lysine structure is located in the interior of the molecule
allowing many active YIGSR sequences on the surface to be
accessible for interactions. Several sizes ofmultimeric YIGSR
peptides, Ac-Y16, Ac-Y8, Ac-Y4, Ac-YI, were previously
synthesised to explore the potentiation of the anti-tumour
effect of the YIGSR peptides and consequently, the larger the
peptide (Ac-Y16 >Ac-Y8 > Ac-Y4 >Ac-Y1), the more inhibi-
tory effect there was on lung colonisation of B16-FIO
melanoma cells (Nomizu et al., 1993).
In the present study, we demonstrated that Ac-Y16 is
active in the attachment of HT1080 cells, inhibits the
attachment of the HT1080 cells to laminin, and reduces
lung colonisation of HT1080 cells. These activities of Ac-Y16
were greater than those of the monomeric synthetic peptide
Ac-YI. We speculate that Ac-YIGSR may inhibit experi-
mental metastasis in part by competing with laminin for the
laminin receptor on tumour cells and thus block the binding
of the cells to the basement membranes.
It has been demonstrated that angiogenesis plays a critical
role in tumour growth and metastasis (Fidler and Ellis, 1994).
The YIGSR sequence has been shown to prevent both the
morphological differentiation of endothelial cells into
capillary-like structures (Grant et al., 1989) and tumour
angiogenesis by blocking the endothelial cell migration
(Sakamoto et al., 1991). Here, we used an in vivo assay,
using the basement membrane extract, Matrigel, to determine
the effect of Ac-Y16 and Ac-Yl on tumour angiogenesis. Co-
injection with HT1080 cells of Ac-Y16 showed inhibition of
both angiogenesis and growth of s.c. tumours. In addition,
the extent of the inhibition by Ac-Y16 was greater than that
by Ac-Y1 (Figure 3 and Table II). Intraperitoneal adminis-
tration of 0.5 mg of Ac-Y16 per day was also effective in
inhibiting angiogenesis, s.c. tumour growth and metastasis
formation (Figure 3, Tables I and II). These results suggest:
(1) Ac-Y16 regulates the growth and the metastasis formation
of HT1080 cells by its effect on angiogenesis; (2) the
multimeric YIGSR peptide enhances the inhibitory effect on
angiogenesis over that observed with the monomeric peptide;
(3) both s.c. and i.p. injections ofmultimeric YIGSR peptides
are effective.
The multimeric peptide has been reported to induce
apoptosis in HT1080 human fibrosarcoma cells in vitro
Table II Effect of laminin-1 peptides on tumour growth
Nwnber ofmice bearing tumourl Tumour weight (mg)
Treatment group number ofmice tested (mean s.e., n=5) (%)
Experiment Ja: co-injection of the peptides with HTO080 cells
Untreated control 5/5 134± 34 (100%)
Ac-YI 5/5 121+ 38 (91%)
Ac-Y16 2/5** 32+ 15*(24%)
Experiment 2b: ip. administration ofAc-Y16
Untreated control 5/5 146+ 36 (100%)
Ac-Y16 5/5 89i 18*(61%)
a Nude mice (five mice per group) were each injected s.c. with 0.3 ml ofMatrigel mixed with 1 x 105 HT1080 cells and peptides (0.5 mg) near the
abdominal midline. Themice were sacrificed on day 14 after the inoculation, the gel plugs were removed and the anti-tumoureffect ofpeptides was
evaluated by weighing the tumour nodules grown in the Matrigel. *P<0.05, Mann -Whitney test. ** Tumour was not detected in three out offive
mice based on histological examination. b Nude mice (five mice per group) were each injected s.c. with 1 x 105 HT1080 cells mixed with 0.3 ml of
Matrigel. The mice were given peptides i.p. daily at a dose of0.5 mg per mouse for 10 days, sacrificed on day 14 after tumour inoculation and the
tumours grown in the Matrigel were weighed. *P<0.05, Mann-Whitney test.
Table HI Effect of Ac-Y16 on growth of both Ehrlich solid and ascitic tumour (n=10 in each case)
Solid tumour Ascitic tumour
[tumour weight (mg)] [Number ofascitic cells ( x 108)]
(meanis.e.) (%) (mean±s.e.) (%)
Treatment On day 9 On day 14 On day 9 On day 14
group after tumour inoculation after tumour inoculation
Untreated 192.4+ 17.8 366.0+ 36.1 2.70± 0.34 3.25+ 0.32
control (100%) (100%) (100%) (100%)
Ac-Y16 17.8 ±3.8* 21.9±2.6* 2.00 ±0.43 3.22± 0.37
(9%) (6%) (74%) (99%)
The effect ofAc-Yl6 on the growth ofthe ascitic tumour was compared with that on the growth ofsolid tumour. Approximately 5 x 106 cells of
Ehrlich ascitic tumour cells suspended in PBS- were mixed with 0.5 mg of Ac-Y16 and then inoculated s.c. near the abdominal midline or
inoculated i.p. into a female DDD mouse. The mice were killed on day 9 or on day 14 after inoculation. In mice bearing solid tumours, the tumours
were removed and weighed immediately after death. In mice bearing ascitic tumours, the ascites were collected and the number ofascitic tumour
cells was counted. *P<0.05, Mann-Whitney test.Anti-tumour effect of a multimoric YIGSR peptide
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(Kim et al., 1994). However, no evidence indicating that Ac-
Y16 induces apoptosis in vivo has been reported. The
following data suggest that Ac-Y16 is not cytotoxic in vivo:
(1) Ac-Y16 significantly inhibited growth of Ehrlich solid
tumour, but it did not affect ascitic tumour growth at all,
even though the same cell source was used (Table III); (2)
The histological examination of Matrigel removed on day 3
revealed that tumour cells co-injected with Matrigel and Ac-
Y16 were viable, as observed in mouse inoculated with
tumour cells alone; (3) Ac-Y16 was effective in blocking lung
colonisation even if its administration was initiated on day 3
after i.v. inoculation of HT1080 cells when tumour cell
attachment was supposed to have occurred (Table I). Anti-
tumour effects of Ac-Y16 are likely to result from anti-
angiogenesis as direct cytotoxicity on tumour cells was ruled
out.
In order to metastasise, tumour cells must enter and then
leave the circulatory system by crossing the barriers formed
by the endothelium and basement membranes, and finally
proliferate in the parenchymal tissue of the target organ
(Liotta, 1984; Roos et al., 1979). Our data suggest that the
multimeric peptide, Ac-Y16, is effective in blocking tumour
cell binding to basement membranes and inhibiting prolifera-
tion at the target organ ofmetastasis. These synergistic effects
of Ac-Y16 suggest the potential usefulness of this compound
for clinical applications in the treatment of metastasis.
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